reninangiotensinaldosteron
system
raa
complex
origin
regard
accord
current
subject
knowledg
two
main
axe
raa
angiotensinconvert
enzym
ace
angiotensin
iiat
receptor
axi
ma
receptor
axi
activ
first
axi
lead
deleteri
effect
includ
vasoconstrict
endotheli
dysfunct
thrombosi
inflamm
fibrosi
therefor
block
compon
axi
highli
ration
commonli
use
therapeut
procedur
ma
receptor
axi
differ
role
sinc
often
oppos
effect
induc
classic
aceang
iiat
axi
posit
effect
ma
axi
discov
altern
way
pharmacotherapi
activ
axi
raa
appear
articl
briefli
describ
new
molecul
affect
raa
name
recombin
human
activ
angiotensin
peptid
nonpeptid
analog
aldosteron
synthas
inhibitor
third
fourth
gener
mineralocorticoid
receptor
antagonist
result
experiment
clinic
studi
encourag
lead
us
believ
new
molecul
support
treatment
cardiovascular
diseas
well
cardiometabol
disord
reninangiotensinaldosteron
system
raa
regul
blood
pressur
fluid
electrolyt
balanc
physiolog
condit
howev
play
also
role
patholog
process
lead
cardiovascular
disord
eg
hypertens
coronari
arteri
diseas
heart
failur
kidney
diseas
drug
block
raa
eg
angiotensinconvert
enzym
inhibitor
acei
angiotensin
ii
receptor
blocker
arb
mineralocorticoid
receptor
antagonist
mra
mainstay
current
pharmacotherapi
cardiovascular
diseas
cvd
moreov
data
suggest
pleiotrop
effect
raa
blocker
sinc
benefici
clinic
effect
raa
inhibit
atherosclerosi
atrial
fibril
postischem
stroke
state
pulmonari
hypertens
diabet
vasculopathi
alzheim
diseas
tumor
angiogenesi
observ
thu
seem
near
futur
pharmacotherapi
raasaffect
agent
could
extend
new
indic
hand
standard
therapeut
procedur
cvd
base
acei
arb
mra
appear
insuffici
sometim
sinc
block
certain
element
raa
pathway
still
unaffect
may
lead
phenomenon
call
raa
escap
may
attenu
clinic
benefit
raa
blockad
raa
escap
observ
either
acei
arb
treatment
renin
angiotensin
ang
accumul
overcam
abil
drug
effect
suppress
raa
moreov
also
aceindepend
pathway
ang
ii
format
reactiv
ang
ii
promot
aldosteron
secret
aldosteron
escap
occur
longterm
arb
therapi
well
due
increas
serum
potassium
level
angiotensin
ii
receptor
type
depend
mechan
furthermor
broad
use
drug
block
raa
limit
signific
incid
side
effect
eg
hyperkalemia
forc
research
new
drug
express
adequ
efficaci
avoid
advers
effect
take
factor
account
wonder
scientist
worldwid
tri
understand
function
raa
better
discov
new
drug
modul
well
expand
indic
inde
new
molecul
affect
raa
name
recombin
human
activ
angiotensin
peptid
nonpeptid
analog
aldosteron
synthas
inhibitor
asi
third
fourth
gener
mra
describ
recent
new
compound
clinic
trial
alreadi
question
aris
whether
new
agent
modul
raa
new
drug
futur
result
experiment
clinic
studi
encourag
lead
us
believ
new
molecul
support
treatment
cvd
accord
current
subject
knowledg
two
main
axe
raa
aceangiotensin
iiat
receptor
axi
ma
receptor
axi
figur
activ
aceang
iiat
caus
deleteri
effect
includ
vasoconstrict
endotheli
dysfunct
thrombosi
inflamm
fibrosi
ma
receptor
axi
differ
role
sinc
often
oppos
effect
induc
classic
aceang
iiat
axi
suggest
activ
raa
action
raa
blocker
depend
balanc
two
axe
demonstr
therapi
acei
arb
prevent
decreas
express
myocardi
infarct
rat
increas
plasma
ang
level
could
evid
drug
effect
due
inhibit
ang
ii
effect
also
due
activ
ma
axi
raa
sinc
posit
effect
ma
axi
discov
altern
way
pharmacotherapi
activ
axi
raa
appear
ma
signal
call
vasoprotect
axi
well
potenti
consid
novel
therapeut
approach
counterbal
aceang
iiat
axi
novel
approach
target
raa
inde
research
exogen
ang
analog
activ
may
effect
treatment
cvd
prevent
treatment
diabet
vasculopathi
metabol
syndrom
angiotensin
element
raa
arous
big
interest
due
opposit
ang
ii
action
presenc
ang
confirm
heart
blood
vessel
kidney
liver
ang
form
mainli
remov
ctermin
phenylalanin
ang
ii
action
ang
also
produc
ang
ace
neutralendopeptidas
ang
exert
action
stimul
specif
gprotein
coupl
ma
receptor
receptor
ma
stimul
lead
among
other
increas
phosphoryl
endotheli
nitric
oxid
synthas
eno
increas
nitric
oxid
releas
addit
augment
prostacyclin
synthesi
suppress
releas
norepinephrin
thu
ang
consid
vasodil
antiarrhythmogen
factor
effect
ang
diabet
cardiovascular
disord
new
research
area
although
alreadi
data
confirm
posit
impact
peptid
glucos
metabol
role
prevent
hyperglycemiainduc
disord
demonstr
masknockout
mice
present
chang
glucos
lipid
metabol
end
condit
resembl
metabol
syndrom
chronic
elev
ang
level
transgen
rat
lead
better
glucos
toler
insulin
sensit
decreas
plasma
triglycerid
cholesterol
level
reduct
adipos
tissu
mass
possibl
mechan
ang
action
glucos
metabol
may
relat
modul
blood
flow
inhibit
fibrosi
therefor
glucagon
insulin
releas
protect
role
ang
cardiovascular
disord
diabet
also
observ
demonstr
ang
attenu
diabet
cardiomyopathi
rat
vasodilatori
antiprolif
antifibrot
properti
furthermor
cardioprotect
effect
peptid
also
relat
decreas
dyslipidemia
howev
therapeut
use
ang
limit
due
unfavor
pharmacokinet
properti
thu
new
strategi
eg
use
cyclodextrin
liposom
deliveri
system
modif
peptidecycl
form
sought
make
clinic
applic
ang
possibl
nonpeptid
ang
analog
wide
studi
far
ang
analog
ave
nonpeptid
oral
activ
physiolog
well
toler
imidazol
deriv
despit
fact
first
studi
ave
come
last
decad
public
demonstr
pharmacodynam
pharmacokinet
agent
first
vitro
studi
ave
took
place
demonstr
novel
compound
caus
subsequ
increas
low
concomit
product
moreov
demonstr
effect
ave
complet
abolish
inhibit
no
blockad
receptor
benefici
effect
ave
confirm
variou
experiment
model
cvd
diabet
tabl
despit
promis
result
experiment
studi
develop
ave
stop
unknown
strateg
reason
peptid
ang
analog
natur
ligand
abl
stimul
gprotein
coupl
receptor
ma
among
other
discov
human
proteom
analysi
result
two
peptid
examin
amino
acid
sequenc
flgyciylnrkrrgdpafkrrlrd
smchrwsravlfpaahrp
respect
import
compound
signific
homolog
ang
known
gprotein
coupl
receptor
ligand
peptid
sever
chemic
structur
monom
cystein
substitut
serin
display
highest
affin
ma
receptor
confirm
experiment
vitro
vivo
model
display
high
like
ave
affin
ma
receptor
favor
effect
cardiovascular
system
confirm
anim
model
cvd
tabl
ang
analog
clinic
trial
major
limit
ang
use
molecul
peptid
short
plasma
halflif
rapidli
degrad
gastrointestin
tract
given
oral
although
attempt
make
ma
stimul
suitabl
clinic
use
oral
activ
deriv
ang
made
ang
analog
enter
clinic
studi
includ
norleu
ang
current
studi
topic
treatment
diabet
one
pharmaceut
compani
aim
initi
clinic
trial
anoth
ang
patient
duchenn
muscular
dystrophi
congenit
muscular
dystrophi
earli
far
posit
effect
muscl
dystrophi
includ
reduct
muscl
fibrosi
increas
muscl
strength
well
normal
cardiac
dysfunct
confirm
experiment
model
monocarboxypeptidas
angiotensinconvert
enzym
homolog
express
heart
kidney
testi
endothelium
coronari
intraren
vessel
renal
tubular
epithelium
show
higher
affin
ang
ii
ang
produc
vasodil
peptid
ang
ang
ii
figur
acei
increas
angiotensin
ang
level
probabl
relat
enhanc
activ
moreov
target
sever
acut
respiratori
syndrom
coronaviru
sar
cov
infect
viru
express
decreas
probabl
contribut
significantli
develop
pulmonari
insuffici
activ
heart
ventricl
primari
pulmonari
hypertens
patient
suggest
could
cardioprotect
enzym
inde
result
experiment
studi
support
thesi
studi
rat
overexpress
show
reduct
blood
pressur
improv
endotheli
function
also
demonstr
lack
gene
lead
increas
adhes
molecul
proinflammatori
cytokin
express
augment
vascular
inflamm
atherogenesi
apo
knockout
mice
moreov
benefit
experiment
model
diabet
demonstr
infect
adenoviru
contain
human
gene
result
improv
fast
glycemia
glucos
toler
increas
pancreat
b
cell
prolifer
limit
apoptosi
diabet
mice
moreov
demonstr
play
protect
role
diabet
nephropathi
experiment
anim
accord
latest
report
chang
gene
express
observ
clinic
studi
type
type
diabet
patient
posit
correl
ratio
variabl
blood
pressur
fast
glycemia
creatinin
level
urin
protein
present
data
prove
potenti
role
prevent
cvd
organ
damag
provok
sustain
hyperglycemia
thu
search
new
molecul
method
modul
activ
requir
one
possibl
activ
ma
axi
use
demonstr
treatment
ang
iiinfus
wildtyp
mice
blunt
hypertroph
respons
express
hypertrophi
marker
reduc
ang
iiinduc
superoxid
product
ang
iimedi
myocardi
fibrosi
effect
associ
reduc
plasma
myocardi
ang
ii
increas
plasma
ang
level
importantli
partial
prevent
develop
dilat
cardiomyopathi
pressureoverload
wildtyp
mice
data
prove
import
neg
regul
ang
iiinduc
heart
diseas
suppress
advers
myocardi
remodel
benefici
effect
also
demonstr
experiment
model
diabet
kidney
injuri
associ
reduct
blood
pressur
decreas
oxid
stress
moreov
block
ang
action
prevent
benefici
effect
lead
systol
dysfunct
result
highlight
key
cardioprotect
role
ang
potenti
therapeut
strategi
cvd
tabl
actual
success
taken
phase
trial
well
toler
healthi
volunt
although
despit
mark
chang
angiotensin
peptid
concentr
cardiovascular
effect
lack
suggest
presenc
compensatori
mechan
healthi
volunt
tabl
second
way
increas
activ
therefor
ang
synthesi
use
agent
modul
gene
express
two
activ
discov
xanthenon
xnt
resorcinolnaphthalein
vitro
studi
show
two
compound
dosedepend
manner
enhanc
activ
approxim
twofold
control
level
howev
due
result
solubl
studi
xnt
research
vivo
xnt
significantli
solubl
resorcinolnaphthalein
thu
commonli
use
vivo
studi
protect
cardiovascular
effect
xnt
confirm
variou
anim
model
cvd
diabet
tabl
recent
antitrypanosom
drug
diminazen
acetur
dize
shown
exert
offtarget
effect
enhanc
activ
vivo
potenti
benefit
dize
therapi
hypertens
complic
demonstr
differ
anim
model
tabl
protect
effect
dize
associ
activ
vasoprotect
axi
lung
raa
decreas
inflammatori
cytokin
improv
pulmonari
vasoreact
enhanc
cardiac
function
recent
report
demonstr
mechan
dize
antihypertens
action
involv
ma
receptor
activ
nodepend
pathway
moreov
shown
treatment
dize
improv
hypercholesterolemiainduc
corpu
cavernosum
injuri
suggest
potenti
target
treat
erectil
dysfunct
cardioprotect
properti
activ
could
mean
futur
use
compound
prevent
cardiac
insuffici
diabet
complic
includ
hemostasi
disturb
result
reduct
lipogenesi
marker
open
new
perspect
metabol
disord
pharmacotherapi
moment
effect
activ
evalu
preclin
studi
aldosteron
final
product
raa
play
crucial
role
pathophysiolog
cardiovascular
system
aldosteron
contribut
endotheli
dysfunct
fibrinolyt
disord
inflamm
oxid
stress
fibrosi
hypertrophi
arrhythmia
lead
progress
cvd
blockad
aldosteron
action
demonstr
extrem
benefici
therapi
cvd
clinic
trial
spironolacton
eplerenon
steroid
mra
investig
potenti
role
aldosteron
mra
varieti
cvd
trial
result
clinic
interest
signific
function
aldosteron
cardiovascular
system
becam
evid
public
outcom
two
clinic
trial
random
aldacton
evalu
studi
rale
eplerenon
postacut
myocardi
infarct
heart
failur
efficaci
surviv
studi
ephesu
moreov
numer
anim
studi
shown
mr
blockad
reduc
cardiovascular
renovascular
cardiometabol
disord
associ
obes
diabet
moreov
prothrombot
effect
aldosteron
show
experiment
model
thrombosi
demonstr
hormon
enhanc
venou
thrombosi
normotens
rat
mechan
involv
primari
hemostasi
fibrinolysi
oxid
stressdepend
pathway
furthermor
mr
blockad
suffici
revers
aldosteron
effect
hemostasi
receptor
eg
glucocorticoid
receptor
gr
also
involv
prothrombot
action
aldosteron
result
show
aldosteron
action
complex
involv
mr
activ
previous
thought
figur
howev
molecular
mechan
aldosteron
action
complet
understood
effect
aldosteron
mediat
via
classic
nuclear
receptor
genom
action
aldosteron
cellmembran
receptor
nongenom
action
aldosteron
altern
pathway
activ
protein
kinas
secondari
messeng
signal
cascad
well
document
aldosteron
supraphysiolog
concentr
also
act
via
gr
recent
demonstr
anoth
import
receptor
aldosteron
act
g
protein
coupl
estrogen
receptor
activ
play
import
role
aldosteronemedi
regul
endotheli
cell
growth
aldosteron
endothelialmedi
regul
vasoreact
multipl
mechan
aldosteron
action
point
need
search
new
strategi
aldosteron
blockad
date
two
steroid
mra
clinic
use
spironolacton
repres
first
gener
nonselect
mra
eplerenon
correspond
second
gener
significantli
improv
select
mr
steroid
receptor
ic
eplerenon
mr
nmoll
less
androgen
progesteron
estrogen
receptor
despit
irrefut
benefici
effect
spironolacton
eplerenon
confirm
patient
heart
failur
kidney
diseas
use
mra
limit
risk
hyperkalemia
especi
patient
renal
disord
fact
hyperkalemia
report
among
elderli
heart
failur
outpati
henc
risk
hyperkalemia
strongest
stimulu
research
third
gener
mra
nonsteroid
cardioselect
thu
exert
less
renal
side
effect
pharmaceut
compani
nonsteroid
mra
clinic
develop
howev
clinic
data
publish
far
although
data
avail
phase
ii
trial
finerenon
development
code
name
bay
show
safeti
efficaci
patient
heart
failur
chronic
kidney
diseas
finerenon
dihydropyridin
deriv
without
ltype
ca
channel
activ
less
rel
affin
steroid
receptor
current
avail
mra
finerenon
uniqu
pharmacodynam
consequ
differ
molecular
properti
similar
spironolacton
eplerenon
finerenon
competit
antagon
mr
although
show
natriuret
effect
sinc
exert
higher
potenc
efficaci
ic
nmoll
except
select
versu
gr
androgen
progesteron
receptor
finerenon
show
cardiac
renal
protect
confirm
preclin
studi
rat
tabl
furthermor
endorgan
protect
activ
pronounc
finerenonetr
rat
compar
eplerenonetr
anim
posit
outcom
preclin
studi
confirm
trial
tabl
safeti
toler
finerenon
studi
mineralocorticoidreceptor
antagonist
toler
studi
art
patient
heart
failur
mildmoder
chronic
kidney
diseas
treatment
finerenon
result
less
hyperkalemia
slower
renal
dysfunct
compar
spironolacton
wherea
cardiac
renal
paramet
least
similar
clinic
studi
finerenon
patient
worsen
chronic
systol
heart
failur
type
diabet
andor
chronic
kidney
diseas
artshf
artsdn
show
posit
outcom
well
howev
longterm
effect
finerenon
investig
phase
iii
studi
treatment
chronic
heart
failur
mr
block
cardiovascular
tissu
particularli
sought
fourth
gener
mra
present
high
tissu
select
cardiovascular
renal
effect
renalspar
profil
combin
na
excret
mild
k
retent
postul
tissu
select
achiev
improv
physiochem
properti
mra
alter
tissu
distribut
interact
novel
mra
coregul
molecul
evid
coregul
heterogen
group
nonreceptor
protein
requir
influenc
nuclear
receptormedi
transactiv
target
gene
expect
interact
novel
mra
certain
coregul
may
allow
modul
mr
activ
select
thu
rather
select
mr
modul
mr
blocker
per
se
may
key
factor
proper
mr
antagon
understand
natur
mrcoregul
interact
may
stimul
ration
design
fourth
gener
mra
bear
mind
harm
effect
aldosteron
fulli
abolish
mr
blockad
sinc
altern
receptor
gr
well
nongenom
mechan
involv
hormon
action
question
aris
whether
block
level
aldosteron
synthesi
would
benefici
case
figur
key
enzym
aldosteron
product
aldosteron
synthas
predominantli
express
adren
gland
also
express
cardiovascular
system
brain
lack
optim
effect
aldosteron
receptor
blockad
initi
research
asi
like
renantiom
fadrozol
initi
develop
aromatas
inhibitor
use
drug
treat
breast
cancer
also
demonstr
potenti
benefit
therapi
cardiovascular
disord
differ
experiment
model
cvd
diabet
tabl
effect
similar
effect
mra
prove
aldosteron
play
key
role
pathogenesi
cvd
consid
aldosteron
may
also
act
mrindepend
pathway
asi
seem
excel
supplement
classic
mra
therapi
prevent
cardiac
insuffici
result
experiment
studi
promis
allow
us
believ
inhibit
aldosteron
synthesi
support
treatment
cvd
follow
experiment
studi
synthes
base
chemic
structur
first
oral
activ
asi
human
use
tabl
potent
inhibitor
also
inhibit
enzym
catalys
final
step
cortisol
synthesi
result
phase
ii
studi
show
patient
primari
hyperaldosteron
character
sever
hypertens
hypokalemia
induc
revers
dosedepend
decreas
plasma
urinari
aldosteron
concentr
massiv
accumul
aldosteron
precursor
deoxycorticosteron
plasma
confirm
inhibit
product
gene
treatment
caus
correct
hypokalemia
mild
decreas
blood
pressur
efficaci
lower
bp
investig
patient
essenti
hypertens
antihypertens
effect
mg
similar
eplerenon
dose
mg
howev
effect
glucocorticoid
axi
limit
use
higher
dose
loss
select
effect
glucocorticoid
axi
may
problem
case
cush
diseas
patient
fact
preliminari
result
multicent
proofofconcept
studi
patient
cush
diseas
achiev
normal
urinari
cortisol
anoth
trial
goal
evalu
effect
cortisol
respons
adrenocorticotrop
hormon
stimul
patient
essenti
hypertens
order
find
maxim
toler
dose
patient
popul
estim
mg
daili
treatment
well
toler
seriou
advers
effect
trial
compar
eplerenon
patient
primari
aldosteron
effect
blood
pressur
plasma
potassium
renin
concentr
four
week
eplerenon
treatment
signific
four
week
treatment
opposit
drug
effect
plasma
aldosteron
concentr
new
inhibitor
alreadi
exist
drug
accord
research
could
use
either
treatment
hyperaldosteronismrel
diseas
precursor
achiev
safer
select
new
asi
moreov
sever
dihydropyridin
ca
channel
blocker
block
ttype
channel
well
bring
upon
inhibit
aldosteron
synthesi
vitro
dihydropiridin
structur
might
base
develop
novel
molecul
dualli
block
aldosteron
synthas
mr
potent
aldosteron
antagon
b
inhibit
ltype
ca
channel
pronounc
antihypertens
effect
combin
treatmentanoth
approach
raa
block
anoth
approach
effect
treatment
cvd
usag
new
combin
agent
modul
raa
mani
clinic
studi
resolvd
charm
aloft
show
efficaci
dual
raa
blockad
base
combin
variou
dose
wellknown
acei
arb
direct
renin
inhibitor
unfortun
sever
clinic
trial
ontarget
altitud
va
nephrond
patient
hypertens
heart
failur
chronic
kidney
diseas
proteinuria
demonstr
benefici
effect
dual
versu
singl
raa
blockad
higher
incid
advers
event
new
combin
agent
affect
raa
occur
recent
accord
latest
network
metaanalysi
xie
et
al
arni
novel
dualact
angiotensin
receptorneprilysin
inhibitor
highest
probabl
effect
therapi
heart
failur
reduc
eject
fraction
compar
acei
andor
arb
efficaci
classic
raa
affect
drug
cvd
wide
known
previous
assum
effect
could
also
relat
activ
regulatori
element
raa
understand
mechan
new
molecul
action
raa
allow
introduct
altern
therapi
thu
elimin
advers
effect
alreadi
use
drug
emerg
novel
drug
may
help
improv
effect
treatment
cvd
may
significantli
broaden
therapeut
potenti
raa
result
basic
experi
clinic
studi
encourag
lead
us
believ
new
molecul
support
treatment
cvd
could
help
manag
cardiometabol
disord
detail
inform
result
experiment
studi
usag
new
agent
affect
raa
enclos
supplementari
file
supplementari
tabl
author
contribut
author
contribut
write
review
articl
read
approv
final
manuscript
overal
layout
content
prepar
figur
write
manuscript
carri
agp
survey
literatur
regard
experiment
studi
use
agent
modul
raa
summari
tabl
perform
ps
pk
survey
literatur
regard
clinic
studi
part
write
perform
kk
mwz
part
write
revis
manuscript
carri
ec
